EFFECTIVENESS OF THERMAL BALLOON ENDOMETRIAL ABLATION IN THE MANAGEMENT OF ABNORMAL UTERINE BLEEDING UNRESPONSIVE TO MEDICAL THERAPY: A PROSPECTIVE OBSERVATIONAL STUDY
Main Article Content
Keywords
Abnormal uterine bleeding; Thermal balloon endometrial ablation; Endometrial thickness; PBAC score; Minimally invasive gynecology; Refractory AUB; Menorrhagia.
Abstract
Background: Abnormal uterine bleeding (AUB) is a prevalent gynecological condition that significantly impairs quality of life, particularly among perimenopausal women. While medical therapy is the first-line treatment, a substantial proportion of women fail to achieve adequate symptom control and require minimally invasive alternatives. Thermal balloon endometrial ablation (TBEA) has emerged as a safe and effective uterus-preserving option for such cases.
Objectives: To evaluate the clinical efficacy, hematological improvement, and safety profile of thermal balloon endometrial ablation in women with AUB refractory to medical management.
Methods: This prospective observational study included 30 women aged 35–50 years with AUB persisting despite at least six months of medical therapy. Baseline assessments included PBAC scoring, pelvic examination, Pap smear, endometrial biopsy, ultrasound evaluation, and hemoglobin estimation. All participants underwent TBEA under anesthesia. Follow-up was conducted at 10 days, 1 month, and 3 months, assessing menstrual outcomes, PBAC score, endometrial thickness, hemoglobin level, and postoperative complications.
Results: The mean pre-treatment PBAC score significantly reduced from 740.0 ± 108.8 to 142.8 ± 189.6 at three months, corresponding to an 80.7% reduction (p < 0.001). Endometrial thickness decreased from 9.24 ± 1.26 mm to 5.55 ± 0.47 mm, a 40% reduction (p < 0.001). Hemoglobin levels showed a significant improvement from 9.43 ± 1.13 g/dL to 9.87 ± 0.76 g/dL (p = 0.027). No major intraoperative or postoperative complications were observed, and patient satisfaction was high at follow-up.
Conclusion: Thermal balloon endometrial ablation is a highly effective and safe treatment modality for AUB refractory to medical therapy. It offers substantial reduction in menstrual blood loss, normalization of endometrial thickness, improvement in hemoglobin levels, and excellent patient satisfaction. TBEA represents a valuable minimally invasive alternative to hysterectomy, particularly in resource-limited settings.
References
2. Fraser IS, Critchley HOD, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29(5):383–390. doi:10.1055/s-0031-1287662
3. Matteson KA, Rahn DD, Wheeler TL, et al. Nonsurgical management of heavy menstrual bleeding: a systematic review. Obstet Gynecol. 2013;121(3):632–643. doi:10.1097/AOG.0b013e3182844248
4. Learman LA, Summitt RL, Varner RE, et al. A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol. 2003;102(3):453–462. doi:10.1016/S0029-7844(03)00579-6
5. Bongers MY, Bourdrez P, Mol BW, et al. Thermal balloon ablation versus rollerball ablation in the treatment of dysfunctional uterine bleeding: randomized controlled trial. BJOG. 2004;111(10):1095–1102. doi:10.1111/j.1471-0528.2004.00243.x
6. Shaw RW, Symonds IM, Tamizian O, et al. Clinical outcomes of thermal balloon endometrial ablation: long-term follow-up of 400 cases. J Minim Invasive Gynecol. 2007;14(1):24–28. doi:10.1016/j.jmig.2006.08.015
7. Munro MG. Abnormal uterine bleeding in perimenopausal women. Clin Obstet Gynecol. 2017;60(2):196–208. doi:10.1097/GRF.0000000000000279
8. Wise LA, Mikkelsen EM, Rothman KJ, et al. A prospective cohort study of body size and risk of uterine leiomyomata. Epidemiology. 2012;23(7):972–981. doi:10.1097/EDE.0b013e31826c2ccb
9. Singh S, Best C, Dunn S, Leyland N, Wolfman WL. Abnormal uterine bleeding in pre-menopausal women. J Obstet Gynaecol Can. 2013;35(5):473–475. doi:10.1016/S1701-2163(15)30910-4
10. Gupta J, Sinha A, Lumsden MA, et al. Uterine cavity length and outcome of endometrial ablation. BJOG. 2010;117(12):1544–1551. doi:10.1111/j.1471-0528.2010.02724.x
11. Dutton C, Hapangama DK. Endometrial thickness as a predictor of outcome in ablation therapies. Obstet Gynecol. 2016;127(1):89–95. doi:10.1097/AOG.0000000000001189
12. James AH. Iron deficiency anemia in women: a global perspective. Blood Rev. 2013;27(4):195–202. doi:10.1016/j.blre.2013.03.003
13. Corson SL, Brill AI, Brooks PG. A clinical evaluation of the thermal balloon ablation system. Am J Obstet Gynecol. 2000;182(6):1395–1401. doi:10.1067/mob.2000.107335
14. Cooper KG, Bain C, Parkin DE. Microwave endometrial ablation vs thermal balloon ablation. Obstet Gynecol. 1999;94(6):913–918. doi:10.1016/S0029-7844(99)00463-3
15. Penninx JP, Herman MC, Mol BW, Bongers MY. Factors predicting successful endometrial ablation. Obstet Gynecol. 2015;126(3):599–606. doi:10.1097/AOG.0000000000001014
16. Singh DK, Sinha N, Kumar R, Bhattacharya S, Maurya A. Identifying the risk factors for the prevention of hypertensive disorders in pregnancy in a tertiary care hospital: A cross-sectional study. J Family Med Prim Care 2020;9:6121-4.
17. Bhattacharya S, Saleem SM, Singh DK, Marzo RR, Singh A. Colour coded client segmentation (CCCS) public health approach to educate the community to deal with problem of hypertension: A pilot study. J Edu Health Promot 2021;10:41
18. Singh DK, Sinha N, Bera OP, Saleem SM, Tripathi S, Shikha D, et al. Effects of diet on hypertensive disorders during pregnancy: A cross-sectional study from a teaching hospital. J Family Med Prim Care 2021;10:3268-72.
19. Singh, A, et al."Pathological Features of Myocardial Infarction in Patients with Pre-existing Hypertension." European Journal of Cardiovascular Medicine, vol. 14, no. 4, 2024, pp. 942-947.
20. Khan F, Sinha N, Kumar R, Singh DK. Comparison of normal and abnormal CTG tracings in labour in terms of pregnancy and early neonatal outcome: Journal of Cardiovascular Disease Research2022;Vol13 Issue10:291-99
